Skip to content
A4667Assembly2021-2022 SessionSame asS4532

Require Abuse-Deterrent Opioids Coverage

Official title

“Limits the substitution of abuse-deterrent analgesic opioid drug products for analgesic opioids lacking such technology”

Sponsor Nader SayeghAD-90Affects Finance
Status
In Assembly Committee
Insurance
Impact
7/10
Significant
Passage
0%

Bill progress

Step 2 of 7

In committee · Insurance

What's happening

This bill requires insurance coverage and equal cost-sharing for at least one abuse-deterrent opioid per active ingredient, prohibiting prior authorization from mandating non-abuse-deterrent opioids first.

Why it matters

  1. Reduces insurance barriers. for patients by ensuring that health plans cannot require people to try non-abuse-deterrent opioids before covering abuse-deterrent formulations, making it easier for prescribers to choose safer options for pain management.

  2. Mandates equal or lower out-of-pocket costs. for abuse-deterrent opioids compared to non-abuse-deterrent versions, potentially increasing patient access to medications designed to reduce misuse and the risk of addiction.

  3. Prevents insurers from shifting costs. to patients or providers as a way of complying—meaning insurers can’t increase copays, coinsurance, or deductibles, nor create financial disincentives for doctors or pharmacists to prescribe or dispense abuse-deterrent opioids.

  4. Could influence prescribing habits and public health. by encouraging the use of abuse-deterrent formulations, which may help address opioid misuse and diversion in New York, while also setting a precedent for insurance policy regarding other high-risk medications.

The daily · weekday mornings

Albany, before your first meeting.

Every bill that moved yesterday, summarized in a sentence and ranked by impact. The Albany Scorecard follows on Sundays.

Free. Unsubscribe in one click. Want alerts on specific bills? Create an account.

Who cares

  • Insurance carriers and health plans

    The bill would require formulary coverage of at least one abuse-deterrent opioid product per opioid active ingredient and prohibit requiring non-abuse-deterrent opioids first.

  • Patients prescribed opioid pain medications

    The bill would cap cost-sharing for covered abuse-deterrent opioids at the lowest level for non-abuse-deterrent opioids in the corresponding brand-name or generic category.

  • Prescribers and pharmacists

    The bill would prohibit disincentives for prescribers or dispensers as a means of complying with its coverage requirements.

  • Manufacturers of FDA-approved abuse-deterrent opioids

    The bill would require coverage of products with FDA-approved abuse-deterrence labeling claims, creating a coverage requirement for this category of medications.

Headline styles

Require Abuse-Deterrent Opioids Coverage

Plain English, a few words. Used as the page title.

Sponsors

Primary sponsor
Nader Sayegh

Assembly Member · Assembly District 90

No co-sponsors yet.

History

  1. Referred to insurance
  2. Referred to insurance

Companion bill

The same bill in the other chamber. A bill becomes law when one version passes both houses and the governor signs it, so either number can carry it.

S4532Senate

Protect Access to Safer Opioids

In Assembly Committee · Insurance · Sponsor Samra Brouk

Impact 7 · Significant0% to pass

Full text

2 pagesUnderlined is new[Struck] is removedOfficial text on nysenate.gov ↗

STATE OF NEW YORK

4667

2021-2022 Regular Sessions

IN ASSEMBLY

February 4, 2021

Introduced by M. of A. SAYEGH -- read once and referred to the Committee on Insurance

AN ACT to amend the public health law and the insurance law, in relation to the use of abuse-deterrent technology for opioids as a mechanism for reducing abuse and diversion of opioid drugs

The People of the State of New York, represented in Senate and Assembly, do enact as follows:

Section 1. Section 273 of the public health law is amended by adding a new subdivision 11 to read as follows:

11. Any prior authorization requirements for opioid analgesic and any service denials made pursuant thereto shall not require use of opioid analgesic drug products without abuse-deterrent properties before authorizing the use of abuse-deterrent opioid analgesic drug products.

§ 2. The insurance law is amended by adding a new section 3216-a to read as follows:

§ 3216-a. Access to abuse-deterrent opioid medications. (a) An insurance carrier or health plan shall provide coverage on its formulary, drug list or other lists of similar construct for at least one abusedeterrent opioid analgesics drug product per opioid analgesics active ingredient.

(1) Cost-sharing for brand name abuse-deterrent opioid analgesic drug products covered pursuant to this section shall not exceed the lowest cost-sharing level applied to brand name non-abuse deterrent opioid drugs covered under the applicable health plan or policy.

(2) Cost-sharing for generic abuse-deterrent opioid analgesic drug products covered pursuant to this section shall not exceed the lowest cost-sharing level applied to generic non-abuse deterrent opioid drugs covered under the applicable health plan or policy.

(3) An increase in patient cost-sharing or disincentives for prescribers or dispensers shall not be allowed to achieve compliance with this section.

EXPLANATION--Matter in italics (underscored) is new; matter in brackets

[ ] is old law to be omitted.

LBD06823-01-1

A. 4667 2

(b) Any prior-authorization requirements or other utilization review measures for opioid analgesics, and any service denials made pursuant thereto, shall not require use of opioid analgesic drug products without abuse-deterrent properties in order to access abuse-deterrent opioid analgesic drug products.

(c) Definitions. As used in this section:

(1) "Opioid analgesic drug product" means a drug in the opioid analgesic drug class prescribed to treat moderate to severe pain or other conditions, whether in immediate release or extended long acting release form and whether or not combined with other drug substances to form a single drug product or other dosage form.

(2) "Abuse deterrent opioid analgesic drug product" means a brand or generic opioid analgesic drug product approved by the federal food and drug administration with abuse-deterrence labeling claims indicating its abuse-deterrent properties are expected to deter or reduce its abuse.

(3) "Cost-sharing" means any coverage limit, copayment, coinsurance, deductible or other out-of-pocket patient expense requirements.

§ 3. This act shall take effect on the one hundred twentieth day after it shall have become a law, and shall apply to all policies and contracts issued, renewed, modified, altered or amended on or after such date.

Reflowed for reading: line numbers and page breaks removed. Cite the official text.

Summaries, headlines and scores are AI-generated from the official bill text. How we score bills. Source: NYS Open Legislation.